Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 2/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 7/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL300907 | 0.89 | CYP3A4 (0.47) | IMPDH2IMPDH1ARSLC22A12CYP3A4 | |
| SCHEMBL29405309 | 0.84 | CYP3A4 (0.50) | CYP3A4ALDH1A1MAPT | |
| SCHEMBL27066 | 0.84 | CYP3A4 (0.50) | CYP3A4ALDH1A1MAPT | |
| SCHEMBL3205617 | 0.81 | ALDH1A1 (0.52) | IMPDH2IMPDH1ARSLC22A12CYP3A4 | |
| SCHEMBL9035492 | 0.80 | IMPDH2 (0.53) | IMPDH2IMPDH1ARSLC22A12CA1 | |
| SCHEMBL11382980 | 0.78 | CYP3A4 (0.45) | CYP3A4ALDH1A1GAAMAPT | |
| SCHEMBL28189098 | 0.78 | CYP3A4 (0.45) | CYP3A4ALDH1A1MAPT | |
| SCHEMBL29489135 | 0.77 | IMPDH2 (0.64) | IMPDH2IMPDH1ARSLC22A12CA1 | |
| SCHEMBL151936 | 0.77 | IMPDH2 (0.64) | IMPDH2IMPDH1ARSLC22A12CA1 | |
| SCHEMBL5788213 | 0.76 | IMPDH2 (0.43) | IMPDH2IMPDH1ARSLC22A12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168667-B2 | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such | GALAPAGOS NV (BE) | 2012-05-01 | — | — | US | disclosed |
| EP-2026799-B1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | GALAPAGOS SAS (FR) | 2011-06-22 | — | — | EP | disclosed |
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | DART THERAPUTICS, LLC. | 2010-08-19 | — | — | US | disclosed |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | SASU, GALAPAGOS (FR) | 2010-03-11 | — | — | US | disclosed |
| US-7632858-B2 | Open chain prolyl urea-related modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632858-B2 | Open chain prolyl urea-related modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-7632858-B2 | Open chain prolyl urea-related modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| EP-2026799-A2 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | Galapagos SAS (FR) | 2009-02-25 | — | — | EP | disclosed |
| US-20080108691-A1 | OPEN-CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| US-20080108691-A1 | OPEN-CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1567487-A2 | OPEN CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20050153968-A1 | Monocyclic N-aryl hydantoin modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-07-14 | — | — | US | disclosed |
| WO-2005049580-A1 | MONOCYCLIC N-ARYL HYDANTOIN MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050059652-A1 | Open chain prolyl urea-related modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-17 | — | — | US | disclosed |
| WO-2004045518-A2 | OPEN CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040092559-A1 | Bicyclic modulators of androgen receptor function | HAMANN LAWRENCE (US) | 2004-05-13 | — | — | US | disclosed |
| EP-1414795-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | Bristol-Myers Squibb Company (US) | 2004-05-06 | — | — | EP | disclosed |
| US-6670386-B2 | For therapy of nuclear hormone receptor-associated conditions, such as age related diseases, for example sarcopenia | BRISTOL-MYERS SQUIBB COMPANY | 2003-12-30 | — | — | US | disclosed |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | BRISTOL-MYERS SQUIBB COMPANY | 2003-03-20 | — | — | US | disclosed |
| WO-2003011824-A1 | BICYCLIC MODULATORS OF ANDROGEN RECEPTOR FUNCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210699-A1 | IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH | NR5A1, AR, HSD17B7 | IMPDH2 1786/4885IMPDH1 979/4885AR 2/4885 |
| US-20030055094-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | IMPDH2 2929/4885IMPDH1 2214/4885AR 1/4885 |
| US-20050059652-A1 | Open chain prolyl urea-related modulators of androgen receptor function | AR, SHBG, ESRRA | IMPDH2 3103/4885IMPDH1 2732/4885AR 1/4885 |
| US-20080108691-A1 | OPEN-CHAIN PROLYL UREA-RELATED MODULATORS OF ANDROGEN RECEPTOR FUNCTION | SHBG, ESRRA, AR | IMPDH2 3101/4885IMPDH1 2747/4885AR 3/4885 |
| US-20050153968-A1 | Monocyclic N-aryl hydantoin modulators of androgen receptor function | AR, NR5A1, CYP19A1 | IMPDH2 1397/4885IMPDH1 1164/4885AR 1/4885 |
| US-20040092559-A1 | Bicyclic modulators of androgen receptor function | AR, NR5A1, ESRRA | IMPDH2 2929/4885IMPDH1 2214/4885AR 1/4885 |
| US-20100063120-A1 | Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such | NR5A1, AR, HSD17B7 | IMPDH2 1755/4885IMPDH1 953/4885AR 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.